Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Post time 1 hour(s) ago

journal：Journal of Clinical Oncology

Authors：Sarah C. Rutherford; Hongli Li; Alex F. Herrera; Michael LeBlanc; Sairah Ahmed; Kelly Davison; Susan K. Parsons; Joseph M. Unger; Anamarija M. Perry; Carla Casulo; Nancy L. Bartlett; Joseph M. Tuscano; Brian T. Hess; Pallawi Torka; Pankaj Kumar; Ryan Jacobs; Joo Y. Song; Sharon M. Castellino; Brad Kahl; John P. Leonard; Sonali M. Smith; Jonathan W. Friedberg; Andrew M. Evens

Published date：2025-9-20

DOI：10.1200/jco-25-00204

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-00204

Article link：https://doi.org/10.1200/jco-25-00204

Article Source：American Society of Clinical Oncology (ASCO)。NEED SUPPLEMENT

Remark：

Post time 1 hour(s) ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Other] Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826